Expected to play a key role in the partnership formation for the company’s drug discovery services which leverage their patented Visikol® HISTO technology and quantitative image analysis software.
Visikol CEO Dr. Michael Johnson today announced that it has appointed Brian Mulhall as Director of Corporate Development effective immediately. In this position, Mr. Mulhall will play a key role in all stages of company operations and development as Visikol works to expand its cutting edge 3D imaging and digital analysis drug discovery platform called 3Screen.
“This is the perfect time for Brian to join the Visikol team. He brings a strong leadership presence to our management group and has extensive experience in building pharma service specific businesses” said CEO Dr. Michael Johnson. “In today’s early stage drug discovery environment, it is critical to operate with cutting edge technology that meets the demanding and fast-paced needs of the pharmaceutical and biotechnology arena. Brian will be effective in helping Visikol improve our operational platform so that we can exceed the demanding research requirements of our clients and help us develop a strategy and vision for long term success.”
In 2015, Mr. Mulhall sold Whitehouse Analytical Laboratories, an FDA regulated testing facility that served the quality control testing needs of the pharmaceutical and biotechnology industries, a company he started in 2002 with business partner Alan Weiss. Previous to Whitehouse Labs, Brian worked for SGS US Testing as a VP of Pharma Services as well as Organon Pharmaceuticals as part of their Executive Management Program.
“I am excited to join the Visikol family and I am highly confident that the 3D imaging product and service platform the scientific team has developed over the past two years offers the drug discovery sector the most up to date tools to expedite the new drug development process. It offers a huge savings in time and expense over existing techniques,” commented Mr. Mulhall.
For the original version on PRWeb visit: